Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLOT-TNT vs FLOT-POP in Gastric or GEJ Cancer (TOGAR)
NCT05567835Phase 2Terminated
- Sponsor
- Baylor College of Medicine
- Start
- Mar 2024
- Primary completion
- Feb 2025
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of fluorouracil, folinic acid, oxaliplatin and docetaxel in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Baylor College of Medicine. Primary endpoint: Completion Rate of Participants Who Have Completed Their All-allocated Treatments at 24 weeks. Started Mar 2024; status: terminated.
02
Drugs
fluorouracilfolinic acidoxaliplatindocetaxel
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05567835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05567835.